The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration ...
Leiden, the Netherlands, May 7, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced presentations at the 2026 Annual Meeting of the ...
Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth ...
As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 ...
The first quarter 2026 financial results and business update will be discussed during a conference call and webcast presentation today at 2:30 PM CET/8:30 AM ET. A webcast of the live call may be ...
The Program is implemented under the following framework: The maximum total consideration for shares bought back under the Program is DKK 1.3 billion. The maximum number of shares that may be acquired ...
On May 7, 2026, Zealand Pharma launched a share buy-back program of up to USD 200 million / DKK 1.3 billion. For more information on the share buy-back program, refer to Zealand Pharma Company ...
Leiden, the Netherlands, May 7, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) presents its preliminary unaudited financial report for the three ...
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
These integrated capabilities will accelerate the shift from broad intervention toward personalised healthcare for patients ...
In 2026, Zealand Pharma expects to receive milestone payments of USD 700 million from Roche, including USD 575 million linked to the initiation of Phase 3 trials with petrelintide monotherapy, ...
CTA approval: On 20 February 2026, Zelluna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) had approved the Company’s Clinical Trial ...
Suja Life, Inc. today announced the pricing of its initial public offering of 8,888,889 shares of its Class A common stock (“Class A Common Stock”) which are being offered by Suja Life as described in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results